Update on utilities and cost-utility analyses.

Sanjay Sharma, Hussein Hollands

Journal: Current opinion in ophthalmology 2007;17(3):223-7

PMID: 16794433

Full Text on Ovid Technologies, Inc. View on PubMed

Abstract

PURPOSE OF REVIEW

The purpose of this review is to summarize the recent and noteworthy utility studies and cost-utility analyses in the area of retina/vitreous during the period January 2004 to January 2006.

RECENT FINDINGS

This review considers the cost-effectiveness of treatments for wet age-related macular degeneration, dry age-related macular degeneration, telemedicine in diabetic retinopathy, and utilities and patients with age-related macular degeneration and diabetic retinopathy.

SUMMARY

Utilities are being used increasingly to measure health-related quality of life. Cost-utility analyses are becoming more readily available for comparing the incremental cost-effectiveness of different ophthalmic interventions.

Address: Cost-effective Ocular Health Policy Unit, Queens University, Kingston, Ontario, Canada.

DOI: 10.1097/01.icu.0000193106.00089.a7

Link outs

Free resources

Medical:

https://medlineplus.gov/maculardegeneration.html

Research Materials:

https://antibodies.cancer.gov/detail/CPTC-BRIP1-5

Subscription / membership required

Full Text Sources:

MeSH Terms: Cost-Benefit Analysis, Economics, Pharmaceutical, Humans, Macular Degeneration